Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: Stalfort John A III (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7144	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred	$		Common Stock (130180)		Direct

Footnotes

F1: Each share of Series A-1 Preferred Stock will automatically convert into the same number of shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred Stock has no expiration date.